New Ways to Treat HCV Infection After Liver Transplant

New direct-acting agents against hepatitis C virus (HCV) can cure the infection when it recurs in patients with liver transplants. Researchers reported findings from 3 separate studies at the 65th Annual Meeting of the American Association for the Study of Liver Diseases last week in Boston. HCV is the leading

Read more

How Can We Tell if Patients are Still at Risk for HCC after HCV Therapy?

For patients with chronic Hepatitis C virus infection, high levels of α-fetoprotein after therapy can identify those at risk for hepatocellular carcinoma (HCC), researchers report in the July issue of Clinical Gastroenterology and Hepatology. In persons with chronic HCV infection, lack of sustained virologic response (SVR) 24 weeks after the end

Read more

Meeting Report: 20th International Symposium on Hepatitis C Virus and Related Viruses

Didn’t make it to the 20th International Symposium on HCV and Related Viruses last fall in Melbourne, Australia? No worries—you can read a summary of the key findings presented at the meeting in the July issue of Gastroenterology. Michael R. Beard et al. report on the latest research into viral entry, replication, and

Read more

Mapping HCV Infection in the Liver

Using single-cell laser capture and high-resolution analysis, researchers show that hepatitis C virus (HCV) infects hepatocytes in the human liver in nonrandom clusters, whereas expression of anti-viral molecules is scattered among hepatocytes. The findings are presented in the December issue of Gastroenterology. HCV predominantly infects hepatocytes, but most hepatocytes in

Read more

Are Patients Receiving the Latest Anti-HCV Drugs?

Less than 20% of patients infected with the most common Hepatitis C virus (HCV) genotype receive the latest drugs approved by the US Food and Drug Administration (FDA), according to the August issue of Clinical Gastroenterology and Hepatology. This low percentage could result from concerns of side effects or patient

Read more

Is SVR12 As Good As SVR24?

In patients with chronic Hepatitis C virus (HCV) infection, a sustained viral response to treatment regimens 12 weeks after therapy (SVR12) is a good indicator that the response will be maintained until week 24 (SVR 24), based on an analysis of pooled clinical trial data published in the June issue of

Read more

New Ways to Study HCV, Genotypes 3 and 4

Researchers can now study replication of Hepatitis C virus genotypes 3 and 4 in cultured cells, described in 2 articles in the January issue of Gastroenterology. These new tools will improve our understanding of how they cause liver disease, and could lead to new treatments. HCV leads to chronic infection

Read more

It’s Not Easy to Diagnose Intermediate-Stage Liver Fibrosis

Biopsy has a low level of diagnostic performance for liver fibrosis stages F2 and F1. The recommendation for biopsy analysis, instead of non-invasive tests, for diagnosis of intermediate stages of fibrosis is therefore misleading, according to the June issue of Clinical Gastroenterology and Hepatology. Noninvasive tests such as FibroTest are

Read more

A Special Issue on Viral Hepatitis

The May issue of Gastroenterology features a very special supplement—“Viral Hepatitis: A Changing Field”—comprising 17 review and commentary articles from international leaders in hepatitis treatment and research. The issue provides insight into the rapid progress made in the treatment and management of patients with viral hepatitis, as well as our

Read more

Can We Treat Chronic HCV Infection Without Interferon?

A potent combination of 2 drugs that directly target the hepatitis C virus (HCV) is effective in patients with chronic infection, and doesn’t require interferon therapy, according to an article in the December issue of Gastroenterology. Patients infected with HCV genotype-1 are usually treated with peginterferon and ribavirin, but approximately

Read more